Shigella Vaccine Shows Promise in Infants and Adults in Positive Phase 2 Trials, Valneva Says
Valneva’s S4V2 vaccine candidate cut shigellosis in a controlled human infection trial and produced strong immune responses in Kenyan infants, in results announced on Monday.